Therapy for Hodgkin’s Lymphoma — Can It Get Any Better?
Mené sur 994 patients atteints d'un lymphome hodgkinien classique de stade avancé, cet essai multicentrique de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout de nivolumab et de brentuximab védotin à une chimiothérapie de type AVD (doxorubicine, vinblastine et dacarbazine)
The approach to Hodgkin’s lymphoma treatment has emphasized the use of chemotherapy agents and radiation therapy to kill cancer cells. In the past, radiation therapy was able to cure some patients with limited-stage Hodgkin’s lymphoma, but most patients continued to die of the disease. However, the publication of results regarding the MOPP regimen (mechlorethamine, vincristine, procarbazine, and prednisone) in 19701 led to a dramatic reduction in deaths from this lymphoma in the United States over the ensuing decade. The ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) was introduced in 1975,2 and subsequent studies showed it to be more effective than (...)